azacitidine has been researched along with Leukemia P388 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahluwalia, GS; Barchi, JJ; Cooney, DA; Covey, JM; Gharehbaghi, K; Hochman, I; Jayaram, HN; Paull, KD | 1 |
| Ahluwalia, GS; Arnold, ST; Balzarini, J; Cohen, MB; Cooney, DA; Dalal, M; Johns, DG; Kang, GJ; McMahon, JB; Wilson, YA | 1 |
| Hickey, I; Ruddy, SM | 1 |
3 other study(ies) available for azacitidine and Leukemia P388
| Article | Year |
|---|---|
Studies on the mechanism of action of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) in mammalian lymphoblasts.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Survival; Deoxycytidine; DNA, Neoplasm; Humans; Leukemia P388; Lymphocytes; Mice; Mice, Inbred Strains; Phosphorylation; Tumor Cells, Cultured | 1996 |
Arabinosyl-5-azacytosine: mechanisms of native and acquired resistance.
Topics: Animals; Azacitidine; Biological Transport; Colonic Neoplasms; Cytidine; Deoxycytidine; Deoxycytidine Kinase; DNA; Drug Resistance; Humans; Leukemia P388; Mice; Phosphorylation | 1986 |
Reversion in thymidine kinase deficient variants of mouse lymphoma P388.
Topics: Animals; Azacitidine; Leukemia P388; Leukemia, Experimental; Mice; Mutation; Thymidine Kinase; Tumor Cells, Cultured | 1989 |